Navigation Links
ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Date:9/19/2011

CAMBRIDGE, Mass., Sept. 19, 2011 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) and Aestus Therapeutics, Inc., announced today the expansion of their current research collaboration agreement to test additional small-molecule compounds for the ability to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).  The expanded scope of this collaboration is based on encouraging results from early-stage animal studies conducted in the past year under the existing collaboration.

(Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)

"This collaboration is an important example of how our Institute, built by the ALS community -, is dedicated to speeding the development of new therapies and has become the leader in preclinical validation of potential treatments for ALS.  We are encouraged by these early results and look forward to expanding our partnership with Aestus on behalf of patients today," says Steve Perrin, Ph.D., president and CEO of ALS TDI.

The original research collaboration was established between ALS TDI and Aestus in March 2010 to test a compound identified by Aestus's proprietary gene-based drug discovery platform in an animal model of ALS. Results obtained by ALS TDI using their rigorous pre-clinical drug testing process were encouraging and warranted expansion of the collaboration to test compounds with a similar mode of action.  

"We at Aestus are delighted to expand our research collaboration with ALS TDI to identify novel therapeutics for this devastating disease," says Tage Honore, Ph.D. D.Sc., CEO and founder of Aestus.  "The expansion of our research agreement with ALS TDI is based on a truly collaborative approach involving scientists at both institutions. We are particularly gratified that the encouraging results from experiments at ALS TDI have helped to furt
'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
2. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
3. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
4. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
5. Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy
6. Genethon and Childrens Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial
7. RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece
8. FDA Approves Dendreons Los Angeles Cancer Immunotherapy Manufacturing Facility
9. Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
10. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
11. Adeona Announces Positive Alzheimers Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 ... announced the addition of Jain PharmaBiotech,s new ... to their offering. ... pharmaceutical and biotechnology industries is anticipated. Nanotechnology ... drug development - from formulations for optimal ...
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
(Date:9/2/2015)... Israel , September 2, 2015 ... announced the intent of the National Institute of Allergy and ... Health (NIH) within the Department of Health and Human Services ... held in the United States in ... BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as a primer ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... , Michael Su, M.S. and Jin Liao, M.D., Ph.D., ... Molecular Devices Corporation, 8/00 , , INTRODUCTION ... pyralis) is very popular foruse in Reporter Gene Assays. The enzyme ... (Figure 1) 1 . When luciferase is the limiting component in ...
... Michael Su, M.S., ... 8/00 , , INTRODUCTION , ... dilutions of samples were necessary to ensure that they fell ... with greatly improved sensitivity and dynamic range, have become commercially ...
... , ... INTRODUCTION , Adenosine triphosphate (ATP) is present ... can be used as a indicator of viable cell number.ATP measurements ... contamination in the food, drug, health care and personalhealthcare industries, as ...
Cached Biology Technology:Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38) 2Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38) 3Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38) 4High Sensitivity, Wide Dynamic Range, Horseradish Peroxidase (HRP) ELISA Using the LMax Microplate Luminometer (MaxLine Application Note #41) 2High Sensitivity, Wide Dynamic Range, Horseradish Peroxidase (HRP) ELISA Using the LMax Microplate Luminometer (MaxLine Application Note #41) 3ATP Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #40) 2ATP Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #40) 3ATP Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #40) 4
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/17/2015)... Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... campaign for Q4 2015. The new marketing campaign is ... of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ... a leader in retail driven marketing and brand awareness ...
(Date:8/12/2015)... JOSE, Calif. , Aug. 12, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... recently announced Match-in-Sensor solution, have officially been named ... Alliance. As part of the certification, Synaptics, Natural ... FIDO 1.0 Universal Authentication Framework (UAF) standard and ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... AWRE ), a leading technology innovator and supplier ... call to discuss the company,s operating results for the third ... Eastern Time. President and CEO Edmund Reiter and CFO Rick ... call is being webcast by Thomson and can be accessed ...
... slice it, watermelon has a lot going for it ... there,s more. Evidence from a pilot study led by food ... be an effective natural weapon against prehypertension, a precursor to ... its kind in humans. FSU Assistant Professor Arturo Figueroa and ...
... ,URBANA When you think about "wine country," Illinois may not ... big business on the prairie. There are 90 wineries licensed in ... wine grapes can bring as much as $8,000 in sales, though ... produce 90,000 gallons per year, while many produce 3,000 to 10,000 ...
Cached Biology News:Aware, Inc. Announces Q3'10 Earnings Conference Call 2Florida State study finds watermelon lowers blood pressure 2Florida State study finds watermelon lowers blood pressure 3Taming wild grapes for better wine 2Taming wild grapes for better wine 3
C1-inhibitor (C1-INH)...
Procollagen type I C-terminal propeptide (human, PICP)...
... provides a comprehensive microarray service for ... embedded within non-coding RNAs (ncRNAs) using ... probe design, which enables highly sensitive ... RNAs (1). This comprehensive service includes ...
... LC micro-fractionation, spotting and preparation for ... LC eluent can be accurately and ... trace amounts. This allows for automatic ... measurements. When used in conjunction with ...
Biology Products: